PharmaLundensis is a research company. The company's main focus is on the treatment of serious lung diseases. Diseases that the company specializes in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced pulmonary failure. In addition to its main business, technical systems for handling drug emissions are developed. PharmaLundensis has its headquarters in Lund.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Staffan Skogvall | 49,14 | 49,14 | 2025-06-26 |
| Vict Th Engwalls Stiftelse | 3,33 | 3,33 | 2025-06-26 |
| Arne Arvidsson | 2,11 | 2,11 | 2025-06-26 |
| Arne Skogvall | 2,08 | 2,08 | 2025-06-26 |
| Avanza Pension | 1,19 | 1,19 | 2025-06-26 |
| Nordnet Pensionsförsäkring | 0,85 | 0,85 | 2025-06-26 |
| Tommy Johansson | 0,81 | 0,81 | 2025-06-26 |
| Staffan Engelbert Bodén | 0,66 | 0,66 | 2025-06-26 |
| Monica Billgert | 0,54 | 0,54 | 2025-06-26 |
| Investment Aktiebolaget Balticum | 0,49 | 0,49 | 2025-06-26 |
2025-11-20 Delårsrapport 2025-Q3
2026-02-19 Bokslutskommuniké 2025
